These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 6238928)

  • 41. Amoxicillin: in vitro susceptibility of "blood culture strains" of gram-negative bacilli and comparisons with penicillin G ampicillin, and carbenicillin.
    Finland M; McGowan JE; Garner C; Wilcox C
    J Infect Dis; 1974 Jun; 129(0):suppl:S132-8. PubMed ID: 4210005
    [No Abstract]   [Full Text] [Related]  

  • 42. In vitro activity of norfloxacin against multi-resistant bacteria.
    Machka K; Vogelsang G
    Eur J Clin Microbiol; 1983 Jun; 2(3):270-1. PubMed ID: 6224686
    [No Abstract]   [Full Text] [Related]  

  • 43. Minimum inhibitory concentrations of some newly developed antimicrobials against common urinary and blood pathogens.
    el-Baz W; Hamid TA; Sabbour MS
    Chemioterapia; 1987 Jun; 6(2 Suppl):40-2. PubMed ID: 3151347
    [No Abstract]   [Full Text] [Related]  

  • 44. Antibacterial activity after a single-dose of norfloxacin, ofloxacin and pipemidic acid detected in urine of volunteers.
    Cruciani M; Monzillo V; Navarra A; Tinelli C; Concia E
    Drugs Exp Clin Res; 1988; 14(8):533-7. PubMed ID: 3150350
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative evaluation of five aminoglycosides for treatment.
    Rosin H; Naumann P; Reintjens E; Köhler M
    Int J Clin Pharmacol Biopharm; 1976 Apr; 13(3):157-67. PubMed ID: 820656
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [In vitro effect of ceftriaxone on hospital bacteria. Line of regression and critical values].
    Cluzel M; Chanal M; Sirot D; Sirot J; Cluzel R
    Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):473-6. PubMed ID: 3937122
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria].
    Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
    Jpn J Antibiot; 2002 Feb; 55(1):22-60. PubMed ID: 11977920
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Study of the in vitro activity of norfloxacin and other drugs on amoxicillin-resistant uropathogenic isolates.
    Piccolomini R; Allocati N; Catamo G
    Chemioterapia; 1984 Jun; 3(3):167-72. PubMed ID: 6241505
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [In vitro effects of cephalexin monohydrate on 1,398 bacterial isolations of various genuses].
    Gonzalez S; Hill JM; Luna M; Gutierrez M; Garcia M; Escarzaga Tapia E
    Prensa Med Mex; 1970; ():11-5. PubMed ID: 4996099
    [No Abstract]   [Full Text] [Related]  

  • 50. Comparison of the antibacterial activity of norfloxacin (MK 0366, AM 715), a new organic acid, with that of other orally absorbed chemotherapeutic agents.
    Gadebusch HH; Shungu DL; Weinberg E; Chung SK
    Infection; 1982 Jan; 10(1):41-4. PubMed ID: 6461606
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Norfloxacin: in vitro activity compared with that of seven other antibacterial agents against urinary tract pathogens.
    Digranes A; Dibb WL; Ostervold B
    Acta Pathol Microbiol Immunol Scand B; 1984 Apr; 92(2):101-6. PubMed ID: 6233841
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bacterial resistance after in vitro exposure to amikacin and netilmicin.
    van de Klundert JA; Vliegenthart JS; Mouton RP
    Eur J Clin Microbiol; 1986 Aug; 5(4):456-8. PubMed ID: 3093226
    [No Abstract]   [Full Text] [Related]  

  • 53. [In vitro antimicrobial activity of pipemidic acid on strains isolated from urine cultures of hospitalized and nonhospitalized subjects].
    Ceddia T; Marinucci MC
    Boll Soc Ital Biol Sper; 1980 Aug; 56(16):1629-32. PubMed ID: 6779836
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In-vitro activity of pefloxacin compared to enoxacin, norfloxacin, gentamicin and new beta-lactams.
    Clarke AM; Zemcov SJ; Campbell ME
    J Antimicrob Chemother; 1985 Jan; 15(1):39-44. PubMed ID: 3156112
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The amount of agar in antimicrobic disk susceptibility test plates.
    Barry AL; Fay GD
    Am J Clin Pathol; 1973 Feb; 59(2):196-8. PubMed ID: 4631582
    [No Abstract]   [Full Text] [Related]  

  • 56. Tobramycin: in vitro antibacterial spectrum of a new aminoglycoside.
    Meyers BR; Hirschman SZ
    J Clin Pharmacol New Drugs; 1972; 12(8):313-20. PubMed ID: 4626620
    [No Abstract]   [Full Text] [Related]  

  • 57. [Effect of ceftazidime on enterobacteria and Pseudomonas producers of beta-lactamases].
    Chabbert YA; Derlot E; Courvalin P
    Pathol Biol (Paris); 1985 Sep; 33(7):758-63. PubMed ID: 3936006
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Bacterial multi-resistence and therapeutic possibilities based on laboratory results].
    Legler F
    Arch Hyg Bakteriol; 1971 Apr; 154(5):517-23. PubMed ID: 4325417
    [No Abstract]   [Full Text] [Related]  

  • 59. Synthesis of novel 5-fluoro analogues of norfloxacin and ciprofloxacin.
    Moran DB; Ziegler CB; Dunne TS; Kuck NA; Lin YI
    J Med Chem; 1989 Jun; 32(6):1313-8. PubMed ID: 2498519
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Evaluation of the in vitro effect of ceftazidime and 12 other antibiotics on gram-negative bacteria isolated from a hospital environment].
    Goglio A; Obiso D; Donadini C; Perani V
    G Ital Chemioter; 1984; 31(3):219-22. PubMed ID: 6442982
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.